Gavi commends donor support of life-saving work through IFFIm
Gavi commends donor support of life-saving work through IFFIm
4 February 2015
Innovative finance tool will continue to provide funding for lifesaving vaccines
Geneva, 4 February 2015 – Gavi, the Vaccine Alliance today thanked the nine sovereign donors whose continued strong support for the International Finance Facility for Immunisation (IFFIm) is helping lifesaving vaccines reach children in developing countries.
At last week’s Gavi Pledging Conference, held in Berlin, Germany, new pledges totalling US$ 252 million were made to IFFIm. These pledges will be added to the US$ 1.2 billion of expected funding from IFFIm for the 2016 to 2020 period from existing commitments of its nine donors: Australia, France, Italy, the Netherlands, Norway, Spain, South Africa, Sweden and the United Kingdom.
IFFIm plays an important role in supporting Gavi. Backed by long-term, legally-binding pledges, IFFIm raises funding through the issuance of Vaccine Bonds in the international capital markets. This provides long-term funding visibility and flexibility for Gavi to rapidly accelerate the immunisation of children in developing countries.
Gavi is deeply grateful to IFFIm’s donors, each of which recognises the long-term importance of IFFIm to the Alliance and confirms its commitment to honouring its pledge to IFFIm.
The US$ 252 million in new pledges made last week to IFFIm saw:
- France increase its long-term pledge by US$ 180 million, adding to its US$ 1.72 billion, 20-year pledge.
- The Netherlands increase its long-term pledge by US$ 72 million and by four years, adding to its US$ 114 million, 8-year pledge.
These new commitments represent a significant increase over the amount pledged to IFFIm at Gavi’s 2011 replenishment conference. In addition, Australia indicated that it may channel a portion of its new US$ 206 million contribution to Gavi through IFFIm.
The US$ 252 million pledged towards IFFIm is part of US$ 7.5 billion in new funding pledged by donors for Gavi’s replenishment. This new funding will be combined with US$ 2 billion in already assured resources – which includes the US$ 1.2 billion previously committed through IFFIm for the 2016-2020 period – to enable Gavi to meet the US$ 9.5 billion cost of funding vaccine programmes in developing countries over the five year period.
Share this article
Restricted Access Library
The material in this Restricted Access Library is intended to be accessed only by persons with residence within the territory of a Member State of the European Union and is not intended to be viewed by any other persons. The material in this Restricted Access Library is provided by IFFIm for information purposes only and the materials contained herein were accurate only as of their respective dates. Certain information in the materials contained herein is not intended to be, and is not, current. IFFIm accepts no obligation to update any material contained herein.
Persons with residence outside the territory of a Member State of the European Union who have access to or consult any materials posted in this Restricted Access Library should refrain from any action in respect of the securities referred to in such materials and are otherwise required to comply with all applicable laws and regulations in their country of residence.
By clicking Access restricted content: DYNAMIC-LINK-TEXT I confirm that I have read and understood the foregoing and agree that I will be bound by the restrictions and conditions set forth on this page.
The materials in this Restricted Access Library are for distribution only to persons who are not a "retail client" within the meaning of section 761G of the Corporations Act 2001 of Australia and are also sophisticated investors, professional investors or other investors in respect of whom disclosure is not required under Part 6D.2 of the Corporations Act 2001 of Australia and, in all cases, in such circumstances as may be permitted by applicable law in any jurisdiction in which an investor may be located.
The materials in this Restricted Access Library and any documents linked from it are not for access or distribution in any jurisdiction where such access or distribution would be illegal. All of the securities referred to in this Restricted Access Library and in the linked documents have been sold and delivered. The information contained herein and therein does not constitute an offer for sale in the United States or in any other country. The securities described herein and therein have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may not be offered or sold in the United States except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws.
Each person accessing the Restricted Access Library confirms that they are a person who is entitled to do so under all applicable laws, regulations and directives in all applicable jurisdictions. Neither IFFIm nor any of their directors, employees, agents or advisers accepts any liability whatsoever for any loss (including, without limitation, any liability arising from any fault or negligence on the part of IFFIm or its respective directors, employees, agents or advisers) arising from access to Restricted Access Library by any person not entitled to do so.
Reflections on IFFIm: an interview with Rachel Turner
14 November 2024